TY - JOUR
T1 - Prospective study of trichomonas vaginalis infection and prostate cancer incidence and mortality
T2 - Physicians' health study
AU - Stark, Jennifer R.
AU - Judson, Gregory
AU - Alderete, John F.
AU - Mundodi, Vasanthakrishna
AU - Kucknoor, Ashwini S.
AU - Giovannucci, Edward L.
AU - Platz, Elizabeth A.
AU - Sutcliffe, Siobhan
AU - Fall, Katja
AU - Kurth, Tobias
AU - Ma, Jing
AU - Stampfer, Meir J.
AU - Mucci, Lorelei A.
PY - 2009/10
Y1 - 2009/10
N2 - Background: A recent nested case-control study found that the presence of antibodies against Trichomonas vaginalis, a common nonviral sexually transmitted infection, was positively associated with subsequent incidence of prostate cancer. We confirmed these findings in an independent population and related serostatus for antibodies against T vaginalis to prostate cancer incidence and mortality.MethodsWe conducted a case-control study nested within the Physicians' Health Study that included 673 case subjects with prostate cancer and 673 individually matched control subjects who had available plasma samples. Plasma from blood samples collected at baseline was assayed for antibodies against T vaginalis with an enzyme-linked immunosorbent assay. We used conditional logistic regression to estimate the odds ratios (ORs) of incident prostate cancer, extraprostatic prostate cancer, and cancer that would ultimately progress to bony metastases or prostate cancer-specific death.ResultsAlthough not statistically significant, the magnitude of the association between T vaginalis-seropositive status and overall prostate cancer risk (OR = 1.23, 95% confidence interval [CI] = 0.94 to 1.61) was similar to that reported previously. Furthermore, a seropositive status was associated with statistically significantly increased risks of extraprostatic prostate cancer (OR = 2.17, 95% CI = 1.08 to 4.37) and of cancer that would ultimately progress to bony metastases or prostate cancer-specific death (OR = 2.69, 95% CI = 1.37 to 5.28).ConclusionsThis large prospective case-control study obtained further support for an association between a seropositive status for antibodies against T vaginalis and the risk of prostate cancer, with statistically significant associations identified for the risk of extraprostatic prostate cancer and for clinically relevant, potentially lethal prostate cancer.
AB - Background: A recent nested case-control study found that the presence of antibodies against Trichomonas vaginalis, a common nonviral sexually transmitted infection, was positively associated with subsequent incidence of prostate cancer. We confirmed these findings in an independent population and related serostatus for antibodies against T vaginalis to prostate cancer incidence and mortality.MethodsWe conducted a case-control study nested within the Physicians' Health Study that included 673 case subjects with prostate cancer and 673 individually matched control subjects who had available plasma samples. Plasma from blood samples collected at baseline was assayed for antibodies against T vaginalis with an enzyme-linked immunosorbent assay. We used conditional logistic regression to estimate the odds ratios (ORs) of incident prostate cancer, extraprostatic prostate cancer, and cancer that would ultimately progress to bony metastases or prostate cancer-specific death.ResultsAlthough not statistically significant, the magnitude of the association between T vaginalis-seropositive status and overall prostate cancer risk (OR = 1.23, 95% confidence interval [CI] = 0.94 to 1.61) was similar to that reported previously. Furthermore, a seropositive status was associated with statistically significantly increased risks of extraprostatic prostate cancer (OR = 2.17, 95% CI = 1.08 to 4.37) and of cancer that would ultimately progress to bony metastases or prostate cancer-specific death (OR = 2.69, 95% CI = 1.37 to 5.28).ConclusionsThis large prospective case-control study obtained further support for an association between a seropositive status for antibodies against T vaginalis and the risk of prostate cancer, with statistically significant associations identified for the risk of extraprostatic prostate cancer and for clinically relevant, potentially lethal prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=70350514580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350514580&partnerID=8YFLogxK
U2 - 10.1093/jnci/djp306
DO - 10.1093/jnci/djp306
M3 - Article
C2 - 19741211
AN - SCOPUS:70350514580
SN - 0027-8874
VL - 101
SP - 1406
EP - 1411
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 20
ER -